Personalized tacrolimus dosing after pediatric kidney transplant
Part of Kidney & urinary clinical trials.
This study helps doctors find the right dose of tacrolimus (a medicine that prevents organ rejection) for children who received a kidney transplant. By using math models and blood test results, the trial aims to make dosing more precise and safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old
- This is your first kidney transplant
- You have been taking tacrolimus regularly for at least one year after your transplant
- You have low rejection risk (less than 20% PRA and no donor-specific antibodies)
- Your medical records and blood test results are complete and available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This non-interventional study looks at how tacrolimus blood levels relate to transplant effectiveness and side effects. It uses your existing medical data to understand whether tacrolimus behaves differently from person to person and how that links to safety.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
This study tests an extended-release version of the anti-rejection drug tacrolimus in children who have already had a stable liver transplant. The goal is to see if the longer-acting capsule works as well as the immediate-release form, potentially simplifying daily medication routines.
Hear when a new Pediatric Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.